ImmunityBio Inc (NASDAQ:IBRX) shares traded 9.31% higher at $3.11 on Wall Street last session.
In accordance with the data, 1 analysts cover ImmunityBio Inc (NASDAQ:IBRX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $5.00, we find $5.00. Given the previous closing price of $2.85, this indicates a potential upside of 75.44 percent. IBRX stock price is now 65.41% away from the 50-day moving average and 28.86% away from the 200-day moving average. The market capitalization of the company currently stands at $2.08B.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $5.00 as their price target over the next twelve months.
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Neutral for ImmunityBio Inc (NASDAQ: IBRX).
In other news, BLASZYK MICHAEL D, Director bought 71,915 shares of the company’s stock on Jun 05. The stock was bought for $198,023 at an average price of $2.75. Upon completion of the transaction, the Director now directly owns 71,915 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02, Director Brennan John Owen bought 25,000 shares of the business’s stock. A total of $70,700 was incurred on buying the stock at an average price of $2.83. This leaves the insider owning 25,000 shares of the company worth $77750.0. Insiders disposed of 46,465 shares of company stock worth roughly $0.14 million over the past 1 year. A total of 80.41% of the company’s stock is owned by insiders.
ImmunityBio Inc (NASDAQ: IBRX) opened at $2.6900 on Friday. During the past 12 months, ImmunityBio Inc has had a low of $1.21 and a high of $7.10. The fifty day moving average price for IBRX is $1.9102 and a two-hundred day moving average price translates $2.4093 for the stock.
The latest earnings results from ImmunityBio Inc (NASDAQ: IBRX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.32, missing analysts’ expectations of -$0.23 by -0.09. This compares to -$0.28 EPS in the same period last year. The company reported revenue of $82000.0 for the quarter, compared to $0.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -30.51 percent. For the current quarter, analysts expect IBRX to generate $20k in revenue.
ImmunityBio Inc(IBRX) Company Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.